Study of a drug combo for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your myeloma has come back after treatment, and you've had up to 3 prior treatments that included a proteasome inhibitor or an immunomodulatory drug (like lenalidomide).
- You have not taken iberdomide before.
- Your blood counts and kidney function are within certain limits (a doctor can check these).
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
This trial tests whether a powerful new two-drug combo (daratumumab plus teclistamab) works better than the usual three-drug combos for people with high-risk multiple myeloma that has come back after just one prior treatment. If you’re in first relapse with high-risk features, this study could offer a promising new option.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.